secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2026-08-10T20:05:14+00:00
Accession:  0001411690-26-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q2 2026 revenue up 21% to $8.2M; fully retires secured convertible debentures
--------------------------------------------------------------------------------

- Q2 revenue $8.2M, up 21% YoY from $6.7M; consumables revenue $4.3M, up 31%.
- Sold 9,219 flow cells (+27% YoY); gross margin 53% vs 52% in Q2 2025.
- Operating expenses $11.5M (+2%); adjusted operating expense $8.7M (-2%).
- Completed full retirement of all Senior Secured Convertible Debentures, releasing asset liens.
- Alex Hastie returned as Chief Scientific Officer; T-ALL study showed OGM detected abnormalities in 97.8% of cases vs 55% by karyotyping.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/0001411690-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169026000043/bngo-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001411690-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer